文献速递心力衰竭与心肌病

缺铁性心力衰竭的三种机制通路

Identification of three mechanistic pathways for iron-deficient heart failure.
PubMed 文献 · Eur Heart J · 2024-01-01

该综述提出缺铁性心力衰竭存在三种机制通路:系统性铁缺乏驱动的心肌细胞铁耗竭(1型)、炎症与去适应介导的骨骼肌与心肌细胞内铁缺乏(2型)、晚期心衰中心肌铁流入减少与流出增加(3型)。三种通路可并存或序贯出现,解释了静脉铁剂在不同患者中疗效差异。

要点

  • 转铁蛋白饱和度<约15%-16%可预测静脉铁剂降低心衰事件风险(1型)。
  • 静脉铁剂改善症状和功能能力不依赖基线血红蛋白或血红蛋白变化(2型)。
  • 晚期心衰心肌铁蛋白变化与系统性缺铁预期相反,补铁仍可预防重构(3型)。

核心结论

  • 缺铁性心力衰竭可能通过三种不同机制通路发生:系统性铁缺乏伴红细胞生成受损、骨骼肌与心肌细胞内铁不成比例耗竭、以及晚期心衰心肌铁流入减少和流出增加。
  • 三种通路并非互斥,可在同一患者中同时或序贯出现。

研究设计与样本

  • 综述类文章,基于现有证据汇总分析缺铁性心力衰竭的机制通路。

主要发现

  • 严重缺铁时红细胞生成可牺牲以向心脏等器官供铁。
  • 明显低铁血症(通常伴贫血)可驱动心肌细胞铁耗竭,损害收缩功能。
  • 转铁蛋白饱和度<约15%-16%预测静脉铁剂降低长期主要心衰事件风险的能力(1型缺铁性心衰)。
  • 炎症和去适应介导的骨骼肌功能障碍伴细胞内骨骼肌细胞铁耗竭,轻度低铁血症可加重,静脉铁剂后症状和功能能力改善不依赖基线血红蛋白或血红蛋白变化(2型缺铁性心衰)。
  • 晚期心衰患者因心肌铁流入减少和流出增加出现心肌铁耗竭,心肌细胞铁蛋白变化与系统性缺铁预期相反;补铁可在无系统性缺铁时预防实验性损伤所致心室重构和心肌病(3型缺铁性心衰)。

关键数值与推荐

  • 转铁蛋白饱和度<约15%-16%预测静脉铁剂降低主要心衰事件风险(长期试验)。
  • 静脉铁剂改善症状和功能能力,不论基线血红蛋白或血红蛋白变化(2型缺铁性心衰)。

临床怎么用

  • 评估缺铁性心力衰竭时需考虑系统性铁指标之外的细胞内铁缺乏机制。
  • 静脉铁剂可用于改善心衰患者症状和功能能力,尤其存在炎症或去适应相关骨骼肌功能障碍时。
  • 晚期心衰患者心肌铁代谢变化与系统性缺铁不一致,补铁可能预防心室重构。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically with anaemia) can drive the depletion of cardiomyocyte iron, impairing contractile performance and explaining why a transferrin saturation < ≈15%-16% predicts the ability of intravenous iron to reduce the risk of major heart failure events in long-term trials (Type 1 iron-deficient heart failure). However, heart failure may be accompanied by intracellular iron depletion within skeletal muscle and cardiomyocytes, which is disproportionate to the findings of systemic iron biomarkers. Inflammation- and deconditioning-mediated skeletal muscle dysfunction-a primary cause of dyspnoea and exercise intolerance in patients with heart failure-is accompanied by intracellular skeletal myocyte iron depletion, which can be exacerbated by even mild hypoferraemia, explaining why symptoms and functional capacity improve following intravenous iron, regardless of baseline haemoglobin or changes in haemoglobin (Type 2 iron-deficient heart failure). Additionally, patients with advanced heart failure show myocardial iron depletion due to both diminished entry into and enhanced egress of iron from the myocardium; the changes in iron proteins in the cardiomyocytes of these patients are opposite to those expected from systemic iron deficiency. Nevertheless, iron supplementation can prevent ventricular remodelling and cardiomyopathy produced by experimental injury in the absence of systemic iron deficiency (Type 3 iron-deficient heart failure). These observations, taken collectively, support the possibility of three different mechanistic pathways for the development of iron-deficient heart failure: one that is driven through systemic iron depletion and impaired erythropoiesis and two that are characterized by disproportionate depletion of intracellular iron in skeletal and cardiac muscle. These mechanisms are not mutually exclusive, and all pathways may be operative at the same time or may occur sequentially in the same patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Packer, Anker, Butler, et al. Identification of three mechanistic pathways for iron-deficient heart failure. Eur Heart J. 2024. PMID: 38733250. doi:10.1093/eurheartj/ehae284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。